EGRX Eagle Pharmaceuticals Inc
1,574
$4.68
$0.07
(1.47%)
| Watchers | 1,574 |
| 52-Wk Low | $3.95 |
| 52-Wk High | $23.52 |
| Market Cap | $61.69M |
| Volume | 19,235.00 |
| 52-Wk High | $23.52 |
| 52-Wk Low | $3.95 |
New York State Common Retirement Fund Reduces Stake in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)Zolmax • 3 months ago
New York State Common Retirement Fund lowered its position in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX Free Report) by 58.1% during the third quarter, according to its most recent disclosure...
Share to Feed
ClariVest Asset Management LLC reduced its holdings in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX Free Report) by 28.9% in the third quarter, according to the company in its most recent Form...
Investors considering a purchase of Eagle Pharmaceuticals, Inc. (EGRX) shares, but tentative about paying the going market price of 5.21/share, might benefit from considering selling puts among...
NEW YORK, Feb. 11, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Eagle Pharmaceuticals, Inc. ( Eagle or the Company ) (NASDAQ: EGRX). Such...
EAGLE PHARMACEUTICALS SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Eagle Pharmaceuticals To Contact...
NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) between August...
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Eagle Pharmaceuticals Investors of a Lead Plaintiff Deadline of February 9, 2024 SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind...
EGRX Investors Have Opportunity to Lead Eagle Pharmaceuticals, Inc. Securities Fraud Lawsuit EGRX Investors Have Opportunity to Lead Eagle Pharmaceuticals, Inc. Securities Fraud Lawsuit PR Newswire...
The Law Offices of Frank R. Cruz reminds investors of the upcoming February 9, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Eagle...
NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals" or the "Company") (NASDAQ: EGRX) of a class action...